ABCG2 and colorectal cancer: In conclusion, our result demonstrated that AZ32 could potently reverse ABCG2-mediated MDR in colorectal cancer by inhibit the transporter activity of ABCG2, which is supported by the predicted binding mode that presented the hydrophobic interactions of AZ32 within the drug binding cavity of ABCG2.